| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8786166 | Clinical Oncology | 2018 | 8 Pages |
Abstract
We have identified a favourable prognostic group in VSCC, with p16-positive patients showing improved outcomes. p16 has the potential to be a predictive marker allowing the identification of women more likely to have a favourable response to radiotherapy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
M.L. Yap, G. Allo, J. Cuartero, M. Pintilie, S. Kamel-Reid, J. Murphy, H. Mackay, B. Clarke, A. Fyles, M. Milosevic,